Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Rick W. Keck"'
Autor:
Rick W. Keck, Omar A. Khan, Jerzy Jankun, Dorota Wątróbska-Świetlikowska, Anna Jelińska, Magdalena Ogrodowczyk, Ibrahim H. Mostafa, Maciej Stawny, Katarzyna Dettlaff, Waldemar Bednarski
Publikováno v:
International Journal of Molecular Medicine
In the United States, the annual incidence of bladder cancer is approximately 70,000 new cases, with a mortality rate of approximately 15,000/year. The most common subtype (70%) of bladder cancer is superficial, namely hte non-muscle invasive disease
Publikováno v:
Experimental and Therapeutic Medicine. 9:2339-2343
Plasminogen activator inhibitor (PAI)-1 is a serpin glycoprotein that can stabilize blood clots by inhibiting fibrinolysis. However, wild-type PAI-1 has the disadvantage of a short half-life of ∼2 h. A very long half-life (VLHL) PAI-1 mutant was de
Publikováno v:
Central European Journal of Immunology. 1:1-4
There is considerable interest in the potential of botanicals in preventing and/or alleviating chronic ailments. Among the most studied botanicals are compounds present in green and black teas. Nontoxic tea polyphenols are potent antioxidants, and th
Publikováno v:
International Journal of Oncology. 44:147-152
The aim of this study was to determine the efficacy of epigallocatechin-3-gallate (EGCG) (Polyphenon E®) in comparison with mitomycin C (MMC) to prevent tumor cell implantation/growth in an animal model of superficial bladder cancer and search for p
Publikováno v:
Oncology Letters
Curcumin, a non-nutritive yellow pigment derived from the rhizome of Curcuma longa (turmeric), is considered to be an established nutraceutical with anticancer activity. Turmeric contains three principal components, curcumin, demethoxycurcumin and bi
Autor:
Rick W. Keck, Steven H. Selman
Publikováno v:
Journal of Urology. 186:702-706
Mitomycin C (Novaplus®) is often instilled intravesically in the postoperative period to prevent tumor cell implantation/regrowth after transurethral tumor resection. In an earlier study EGCG prevented tumor cell implantation/growth in an experiment
Autor:
Wiesława Łysiak-Szydłowska, Jerzy Jankun, Steven H. Selman, Ewa Skrzypczak-Jankun, Rick W. Keck
Publikováno v:
BJU International. 105:1469-1476
OBJECTIVE To investigate the potential for the future clinical use of a very long half-life plasminogen activator inhibitor type 1 (VLHL PAI-1) as a haemostatic agent. MATERIALS AND METHODS We developed a VLHL PAI-1 (half-life >700 h) recombinant mut
Publikováno v:
Journal of Urology. 181:1901-1906
Purpose: Tumor spillage from bladder perforation during transurethral bladder tumor resection or cystectomy risks seeding the peritoneum with transitional cell carcinoma. We determined the lowest effective mitomycin C dose to prevent tumor implantati
Application of Long-Acting VLHL PAI-1 during Sutureless Partial Nephrectomy in Mice Reduces Bleeding
Publikováno v:
BioMed Research International, Vol 2015 (2015)
BioMed Research International
BioMed Research International
PAI-1 prevents lysis of blood clot by inhibiting the urokinase and tPA induced conversion of plasminogen to plasmin. VLHL PAI-1 protein mutant was created to extend half-life over 700 hours. The objective of this paper was to test VLHL PAI-1 effects
Autor:
Julian A. Davies, Gongjun Ji, Bernd Radüchel, Nicholas Richardson, Daniel D. Schwert, Wolfgang Ebert, Rick W. Keck, Peter E. Heffner
Publikováno v:
Journal of Medicinal Chemistry. 48:7482-7485
Two 3,5-disubstituted sulfonamide catechol ligands were synthesized. Tris(ligand) iron(III) complexes were prepared and investigated as MRI contrast agents. Longitudinal relaxivity (r1) values were determined for the complexes. The r1 values in water